Can You Take Mounjaro After Wegovy — and What Does the Evidence Say?

What the trial data tells us before you decide anything

The strongest head-to-head evidence comes from SURMOUNT-5, published in the New England Journal of Medicine in 2025. Over 72 weeks, adults with obesity who had no diabetes lost more body weight on average with tirzepatide (Mounjaro) than with semaglutide 2.4 mg (Wegovy), with tirzepatide producing roughly 20–21% average reduction at the highest dose versus approximately 15% for semaglutide at its standard 2.4 mg maintenance dose. NICE's appraisal of tirzepatide (TA1026) notes that indirect comparisons broadly favour tirzepatide, though it acknowledges the limits of cross-trial inference.

That gap narrows with the higher 7.2 mg semaglutide dose approved by the MHRA in early 2026, which produced around 20.7% average weight loss over 72 weeks in trials. So the picture is not static. What matters for any individual is which medicine their prescriber judges most appropriate given their history, tolerability experience, and clinical profile, not which headline percentage looks larger.

If you are already established on Wegovy and wondering whether switching direction or moving across makes sense, the trial data is a reasonable starting point for the conversation, but it does not substitute for one.

How Mounjaro and Wegovy actually differ, and why it matters when switching

Wegovy contains semaglutide, a GLP-1 receptor agonist. Mounjaro contains tirzepatide, which activates both the GLP-1 and GIP receptors, the only dual-agonist weight-loss medicine licensed in the UK. That second pathway is why the two are not interchangeable in a simple dose-equivalence sense: there is no established conversion formula between them.

Both slow gastric emptying, reduce appetite, and are taken as once-weekly subcutaneous injections. Both carry a Black Triangle (▼) status, meaning the MHRA is actively collecting additional safety data. The side-effect profile for both is largely gastrointestinal (nausea, loose stools, constipation, reflux) though the timing and intensity can differ between individuals and between medicines.

For a fuller side-by-side look at licensed indications, trial figures, and NICE criteria, the Wegovy vs Mounjaro comparison covers the ground in detail. The short version: the mechanism differs, the dosing ladder differs, and the prescriber needs to treat any switch as a fresh clinical decision rather than a continuation.

What switching from Wegovy to Mounjaro actually involves in practice

There is no published UK clinical protocol setting out an exact washout period between semaglutide and tirzepatide for weight management. Both medicines have a half-life measured in days (semaglutide's is roughly a week) so there is an overlap risk if both are taken simultaneously. Taking Mounjaro and Wegovy at the same time is not appropriate; concurrent use is outside the licensed indication for either medicine and carries an additive risk of GI side effects and other harms.

In practice, a prescriber reviewing a switch request will typically want to know: why you are switching (insufficient weight loss, side effects, tolerability, supply), what dose of Wegovy you are currently on, and whether any clinical changes have occurred since your original assessment. They may advise completing the current pen, waiting a defined interval, and restarting tirzepatide at the beginning of its own titration schedule, 2.5 mg is the starting point, not whichever dose of semaglutide you were taking.

Transfer patients at nume provide evidence of their current treatment as part of the consultation. Our clinical team, led by our clinical director, reviews each transfer individually, no automated approvals, no skipping the titration ladder. Once approved, the first Mounjaro KwikPen is dispatched the same day and tracked to your door via DPD, arriving the next working day in a plain, unmarked box.

If you are considering the reverse route (moving from Mounjaro to Wegovy) the same principles apply. The moving from Mounjaro to Wegovy page covers that direction specifically.

Cost context and how to assess the decision properly

Since Eli Lilly raised Mounjaro's UK list price from 1 September 2025, the highest-dose pen's list price moved to around £330, with private prices across providers typically ranging from roughly £149 to £375 per month depending on dose and service. Wegovy private pricing sits in a comparable range. A detailed breakdown of what those numbers do and don't include is on the Wegovy vs Mounjaro cost page, and it is worth reading before treating price as the deciding factor in a switch.

For a prescription medicine, price is rarely the right metric. Clinical suitability, supply reliability, and ongoing monitoring matter considerably more. If you want to explore whether taking Wegovy with Mounjaro is something your prescriber might consider as part of your options, that page explains the clinical position clearly before you take the question further. Which medicine suits you (and whether switching makes clinical sense) is a decision our prescribers make with you, not for you.